CyberKnife® Radiosurgery for Brainstem Lesions
During this webinar, “CyberKnife Radiosurgery for Brainstem Lesions”, Dr. Wang will present SRS, hypofractionated stereotactic radiosurgery, and staged SRS for the brain stem lesions from brain metastasis, glioma to cavernous hemangioma, etc with Huashan CyberKnife Center’s experiences. The objective is to share the efficacy and safety with CyberKnife for brainstem lesions treatment.
Ultra-Hypofractionated Partial Breast Radiotherapy
The webinar will focus on ultra-hypofractionated partial breast radiotherapy. Outcomes, ongoing trials, and future trends in accelerated partial breast irradiation (APBI) will be presented by Frank Vicini, M.D. Asal Rahimi, M.D. will share her clinical experience of Stereotactic Body Radiation Therapy (SBRT) for APBI. Mark Perman, M.D. and Debra Freeman, M.D. will share information on the protocol and data collection for the Registry for Performance and Clinical Outcomes in Radiosurgery (RPCR) APBI and Breast SBRT.
The Fusion Experience Launch Event
Powerful synergies lead to meaningful innovations. As we work to improve patient outcomes, Accuray and Brainlab partner to enable the stereotactic radiosurgery community to leverage the precision of Accuray CyberKnife® treatment delivery system in combination with Brainlab Elements planning software.
Stereotactic Body Radiotherapy for Spinal Metastasis: an Overview of Doses and Fractionation
The webinar will focus on the dose and fractionation of spine SBRT referring to the latest published studies. Primary SBRT and reirradiation will be addressed, as well as recent data on doses/fractionation. Case reports will be shared demonstrating clinical and technical aspects of spinal SBRT delivery.
Prostate SBRT and the PACE-B trial
Define the current best practice for prostate Stereotactic Body Radiation Therapy (SBRT). Describe the evidence underpinning prostate SBRT practice. Discuss the recently released data from the international PACE-B trial, which randomized patients between standard fractionation radiotherapy and five fraction SBRT.
25 Years of SBRT with CyberKnife
Dr. Anand Mahadevan is the Professor and Chairman of Radiation Oncology and Dr. Jimm Grimm is the Lead CyberKnife Physicist at Geisinger Medical Center.
Glioblastoma re-irradiation with the CyberKnife® System
“Because most patients with glioblastoma (GBM) will recur, mainly within the first radiation therapy (RT) volume, consequently the question of re-RT, post or instead of reoperation, is critical in our daily practice. As there is no standard in this situation of first recurrence, it seems relevant to share and exchange with the neuro-oncologic community about our 10-year experience of GBM re-irradiation, with and without concomitant Bevacizumab, particularly with the CyberKnife system, which holds in our opinion a very unique place.”
New Evidence for Hepatocellular Carcinoma SBRT Treatment with the CyberKnife® System
In this webinar Dr. Song will discuss how survival outcomes for patients with small-sized hepatocellular carcinoma undergoing SBRT are comparable to those following surgical resection and radiofrequency ablation, and how SBRT could be a bridging therapy for hepatocellular carcinoma prior to liver transplantation.
MyAccuray: Accuray Synchrony® Raises the Bar in AAPM MArkerless Lung Target Tracking Challenge
Delivering effective and safe lung cancer stereotactic body radiation therapy (SBRT) requires technology that can account for lung tumor motion. Both fiducial-based and markerless tracking algorithms currently exist, with markerless being a focus of innovation, investment and research in the field. These tracking algorithms, however, have not been benchmarked using a common, prospective measurement methodology. The American Association of Physicists in Medicine (AAPM) designed the MArkerless Lung Target Tracking CHallenge (MATCH), an AAPM Grand Challenge, to compare the precision and accuracy of existing markerless tracking algorithms.
Tips and Tricks to Treat Central Lung Tumors with the CyberKnife® System
Dr. Nuyttens will share his 15 years of experience in treating lung lesions with the CyberKnife System. He will focus on how effectively central lung tumors can be treated, the challenges faced and how he manages to deliver the most effective dose. Dr. Nuyttens will show actual cases, planning, dose constraints and clinical outcomes.
